JP2014517038A5 - - Google Patents

Download PDF

Info

Publication number
JP2014517038A5
JP2014517038A5 JP2014515934A JP2014515934A JP2014517038A5 JP 2014517038 A5 JP2014517038 A5 JP 2014517038A5 JP 2014515934 A JP2014515934 A JP 2014515934A JP 2014515934 A JP2014515934 A JP 2014515934A JP 2014517038 A5 JP2014517038 A5 JP 2014517038A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
wound
skin
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014515934A
Other languages
English (en)
Japanese (ja)
Other versions
JP6005736B2 (ja
JP2014517038A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/042165 external-priority patent/WO2012174056A1/en
Publication of JP2014517038A publication Critical patent/JP2014517038A/ja
Publication of JP2014517038A5 publication Critical patent/JP2014517038A5/ja
Application granted granted Critical
Publication of JP6005736B2 publication Critical patent/JP6005736B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014515934A 2011-06-13 2012-06-13 Il−12を用いる皮膚損傷の軽減 Active JP6005736B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161496472P 2011-06-13 2011-06-13
US61/496,472 2011-06-13
US201161528053P 2011-08-26 2011-08-26
US61/528,053 2011-08-26
PCT/US2012/042165 WO2012174056A1 (en) 2011-06-13 2012-06-13 Mitigation of cutaneous injury with il-12

Publications (3)

Publication Number Publication Date
JP2014517038A JP2014517038A (ja) 2014-07-17
JP2014517038A5 true JP2014517038A5 (pt-PT) 2015-07-30
JP6005736B2 JP6005736B2 (ja) 2016-10-12

Family

ID=47357436

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014515934A Active JP6005736B2 (ja) 2011-06-13 2012-06-13 Il−12を用いる皮膚損傷の軽減

Country Status (5)

Country Link
US (1) US9925246B2 (pt-PT)
EP (1) EP2718456B1 (pt-PT)
JP (1) JP6005736B2 (pt-PT)
CA (1) CA2839261A1 (pt-PT)
WO (1) WO2012174056A1 (pt-PT)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018017571A1 (en) * 2016-07-18 2018-01-25 Neumedicines, Inc. Uses of il-12 as a replacement immunotherapeutic
JP7045671B2 (ja) * 2018-11-12 2022-04-01 有限会社バイオ研 皮膚塗布用の皮膚創傷治癒促進組成物、その製造方法、及び創傷被覆材
JP7448137B2 (ja) 2020-03-10 2024-03-12 日本ゼトック株式会社 アクチン重合促進剤

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5457038A (en) 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
US6683046B1 (en) 1989-12-22 2004-01-27 Hoffmann-La Roche Inc. Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
US5573764A (en) 1994-01-21 1996-11-12 Genetics Institute, Inc. Use of interleukin-12 to prevent graft versus host disease
AU695129B2 (en) 1995-02-06 1998-08-06 Genetics Institute, Llc Formulations for IL-12
US5853714A (en) 1995-03-27 1998-12-29 Genetics Institute, Inc. Method for purification of IL-12
EP1030680A4 (en) * 1998-09-15 2003-05-02 Genetics Inst TREATMENT OF CAPOSISARCOMA WITH IL-12
US7052685B1 (en) 1998-10-15 2006-05-30 Trustees Of The University Of Pennsylvania Methods for treatment of cutaneous T-cell lymphoma
CA2471363C (en) * 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
ES2367302T3 (es) 2002-12-23 2011-11-02 Schering Corporation Usos de la citoquina il-23 de mamífero; reactivos relacionados.
US7763256B2 (en) 2002-12-23 2010-07-27 William Marsh Rice University Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation
JP5517394B2 (ja) * 2003-07-03 2014-06-11 ユニバーシティ オブ サザン カリフォルニア 造血におけるil−12の使用
US7939058B2 (en) * 2003-07-03 2011-05-10 University Of Southern California Uses of IL-12 in hematopoiesis
RU2387455C2 (ru) 2004-08-20 2010-04-27 Смитклайн Бичам Корпорейшн Способы заживления ран введением il-18 человека
US8165819B2 (en) 2006-10-10 2012-04-24 The University of Pittsburgh—Of the Commonwealth System of Higher Education Modeling wound healing
WO2010135655A2 (en) * 2009-05-21 2010-11-25 Stratatech Corporation Human skin substitutes expressing il-12

Similar Documents

Publication Publication Date Title
HRP20170056T2 (hr) Terapija male učestalosti glatiramer acetatom
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
HRP20120349T1 (hr) Formulacija glatiramer acetata smanjenog volumenai postupci davanja
EA201490377A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата
Lingzhi et al. Biological approaches for hypertrophic scars
NZ707377A (en) Combination therapy methods for treating proliferative diseases
JP2012041342A5 (pt-PT)
MX369385B (es) Productos para cicatrizar heridas tisulares.
EA200971053A1 (ru) Способы лечения кожных язв
MY157564A (en) Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
MX2009011900A (es) Curacion de herida diabetica.
JP2017501154A5 (pt-PT)
JP2014139255A5 (pt-PT)
Kazancioglu et al. Effect of caffeic acid phenethyl ester on bone formation in the expanded inter-premaxillary suture
JP2015532293A5 (ja) 糖尿病患者における心不全の治療用組成物
RU2015116264A (ru) Композиции и способы лечения сердечной недостаточности у пациентов с диабетом
JP2014517038A5 (pt-PT)
SG10201908089VA (en) Novel dosing regimens of celgosivir for the treatment of dengue
Makedonova et al. Studying clinical and pathomorphological changes in gingival tissues when applying platelet-rich autoplasma regenerative method
JP2013520447A5 (pt-PT)
MX336278B (es) Composiciones y metodos para la prevencion y el tratamiento de heridas.
JP2003528919A5 (pt-PT)
RU2016103098A (ru) Способ предотвращения и/или лечения хронической травматической энцефалопатии - ii
BR112012000773A2 (pt) Método para o tratamento de pelo menos uma condição escolhida entre dor, inflamação e febre em pacientes humanos, método para o tratamento de pacientes humanos, método para o tratamento de pelo menos uma condição escolhida entre dor, inflamação e febre em pacientes criticamente doentes, e método para o tratamento de pelo menos uma condição escolhida entre dor, inflamação e febre em pacientes criticamente doentes com risco aumentado de eventos cardiovasculares
RU2015148636A (ru) Модуляция активности гепарин-связывающего эпидермального фактора роста для заживления барабанной перепонки